Kamada
$ 6.99
-0.99%
27 Jul - close price
- Market Cap 403,283,000 USD
- Current Price $ 6.99
- High / Low $ 7.09 / 6.93
- Stock P/E 19.97
- Book Value 4.50
- EPS 0.35
- Next Earning Report 2026-08-12
- Dividend Per Share $0.25
- Dividend Yield 3.54 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.08 %
- 52 Week High 9.07
- 52 Week Low 6.31
About
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
Analyst Target Price
$13.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-11 | 2025-11-10 | 2025-08-13 | 2025-05-14 | 2025-03-05 | 2024-11-13 | 2024-08-14 | 2024-05-08 | 2024-03-06 | 2023-11-13 | 2023-08-16 |
| Reported EPS | 0.07 | 0.06 | 0.09 | 0.13 | 0.07 | 0.07 | 0.07 | 0.08 | 0.04 | 0.09 | 0.06 | 0.04 |
| Estimated EPS | 0.12 | 0.1 | 0.09 | 0.09 | 0.07 | 0.0533 | 0.07 | 0.06 | 0.07 | 0.05 | 0.02 | 0.03 |
| Surprise | -0.05 | -0.04 | 0 | 0.04 | 0 | 0.0167 | 0 | 0.02 | -0.03 | 0.04 | 0.04 | 0.01 |
| Surprise Percentage | -41.6667% | -40% | 0% | 44.4444% | 0% | 31.3321% | 0% | 33.3333% | -42.8571% | 80% | 200% | 33.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.12 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Apr 2025 | |
|---|---|---|
| Payment Date | 2026-04-07 | 2025-04-07 |
| Amount | $0.25 | $0.2 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KMDA
2026-07-27 05:41:06
This article provides details on Kamada Ltd's (KMDA) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays current stock information such as price, market cap, and P/E ratio, while also indicating no historical dividend data.
2026-07-27 03:41:06
This article provides a detailed breakdown of Kamada Ltd (KMDA) shareholder structure, including major individual and institutional investors. It lists the top shareholders and their proportionate holdings, categorizes shareholders by type (e.g., Private Equity, Investment Advisor), and tracks institutional shareholding over several quarters. Key financial metrics like market cap and P/E ratio are also mentioned.
2026-07-26 11:41:11
This article provides a detailed cash flow statement for Kamada Ltd (KMDA), covering quarterly and annual data for operating, investing, and financing activities. It includes breakdowns of various cash flow components, year-over-year percentage changes, and specific monetary figures. The content aims to help users evaluate the financial health and stability of Kamada Ltd.
2026-07-24 23:09:29
Kamada Ltd. (NASDAQ: KMDA) reported a total revenue of $180.46 million USD last year. The majority of this revenue, $169.09 million USD, came from its Proprietary Products segment, an increase from $143.70 million USD in the previous year. The United States was the largest geographical contributor, accounting for $107.86 million USD in revenue.
2026-07-24 10:22:00
Kamada Ltd. (NASDAQ: KMDA) shows significant potential upside of 86.78%, trading at $6.96 with an average analyst target of $13.00. The company, specializing in plasma-derived protein therapeutics, boasts a diverse product portfolio and a 3.60% dividend yield. Despite mixed technical indicators, analyst sentiment is overwhelmingly positive, suggesting Kamada could be an attractive investment in the healthcare sector.
2026-07-22 12:40:43
Kamada Ltd. (ISIN IL0010952647) is an Israeli biopharmaceutical company focused on plasma-derived and specialty therapies for rare and serious conditions. The company's revenue of approximately $100 million annually is driven by sales of plasma-derived products and contract manufacturing, providing a stable income stream. Kamada's strategy emphasizes orphan and niche indications, allowing for premium pricing and limited competition, though its smaller-cap status means its stock behavior is highly sensitive to company-specific events and regulatory changes.
